UBS lowered the firm’s price target on Teva (TEVA) to $23 from $24 and keeps a Buy rating on the shares. Despite steady execution progress on its mid- and long-term outlook, shares are down 20% year-to-date, and UBS thinks the stock has been penalized more unfairly than most of the rest of biopharma. Teva management has addressed multiple investor concerns by stabilizing U.S. generics, rekindling Austedo growth from a sleeper, proved R&D execution, and solving the Revlimid cliff, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- MedinCell initiated with an Outperform at Evercore ISI
- Teva Pharmaceutical’s Strategic Edge and Growth Potential: Analyst Recommends Buy Rating
- Teva, Fosun Pharma partner to develop TEV-56278
- Teva, Fosun enter strategic partnership to develop TEV-56278
- Teva put volume heavy and directionally bearish